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Abstract: BACKGROUND Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-
specific antibody tests are increasingly used to estimate the prevalence of SARS-CoV-2 infection, the
determinants of these antibody responses remain unclear. OBJECTIVES To evaluate systemic and
mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-
19) cases. METHODS Using immunoassays specific for SARS-CoV-2 spike proteins, we determined
SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids
of two cohorts, including SARS-CoV-2 polymerase chain reaction (PCR)+ patients (n = 64) as well as
PCR+ and PCR− healthcare workers (n = 109). RESULTS SARS-CoV-2-specific serum IgA titers in
mild COVID-19 cases were often transiently positive, whereas serum IgG titers remained negative or
became positive 12-14 days after symptom onset. Conversely, patients with severe COVID-19 showed a
highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very
high titers of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome
(ARDS). Interestingly, some healthcare workers with negative SARS-CoV-2-specific serum antibody titers
showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-
CoV-2-specific IgA titers in nasal fluids inversely correlated with age. CONCLUSIONS Systemic antibody
production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA titers seen
in patients with severe ARDS, whereas mild disease may be associated with transient production of
SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion.
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GRAPHICAL ABSTRACT
Background: Whereas severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)-specific antibody tests are
increasingly being used to estimate the prevalence of SARS-
CoV-2 infection, the determinants of these antibody responses
remain unclear.
Objectives: Our aim was to evaluate systemic and mucosal
antibody responses toward SARS-CoV-2 in mild versus severe
coronavirus disease 2019 (COVID-19) cases.
Methods: Using immunoassays specific for SARS-CoV-2 spike
proteins, we determined SARS-CoV-2–specific IgA and IgG in
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sera and mucosal fluids of 2 cohorts, including SARS-CoV-2
PCR-positive patients (n 5 64) and PCR-positive and PCR-
negtive health care workers (n 5 109).
Results: SARS-CoV-2–specific serum IgA titers in patients with
mild COVID-19 were often transiently positive, whereas serum
IgG titers remained negative or became positive 12 to 14 days
after symptom onset. Conversely, patients with severe COVID-
19 showed a highly significant increase of SARS-CoV-2–specific
serum IgA and IgG titers after symptom onset. Very high titers
of SARS-CoV-2–specific serum IgA were correlated with severe
acute respiratory distress syndrome. Interestingly, some health
care workers with negative SARS-CoV-2–specific serum
antibody titers showed SARS-CoV-2–specific IgA in mucosal
fluids with virus-neutralizing capacity in some cases. SARS-
CoV-2–specific IgA titers in nasal fluids were inversely
correlated with age.
Conclusions: Systemic antibody production against SARS-CoV-
2 develops mainly in patients with severe COVID-19, with very
high IgA titers seen in patients with severe acute respiratory
distress syndrome, whereas mild disease may be associated with
transient production of SARS-CoV-2–specific antibodies but
may stimulate mucosal SARS-CoV-2–specific IgA secretion. (J
Allergy Clin Immunol 2020;nnn:nnn-nnn.)
Key words: COVID-19, SARS-CoV-2, SARS-CoV-2–specific anti-
bodies, SARS-CoV-2–specific IgA, SARS-CoV-2–specific IgG, hu-
moral immune response, mucosal immune response, COVID-19
severity, COVID-19 seroprevalence
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the causative agent of coronavirus disease 2019 (COVID-19),
is a Betacoronavirus related to severe acute respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory syndrome
coronavirus.1-4 The zoonotic introduction of Middle East respira-
tory syndrome coronavirus and SARS-CoV into the human pop-
ulation resulted in limited outbreaks, whereas the appearance of
SARS-CoV-2 has led to a rapidly spreading pandemic. As of
October 05, 2020, COVID-19 had been confirmed to have
affected about 35.2 million individuals worldwide and caused
an estimated 1.04 million deaths.5 Several characteristics of
SARS-CoV-2 have likely contributed to its rapid spread. These
include the ability of SARS-CoV-2 to efficiently replicate in the
upper respiratory tract mucosa of humans,6 its variable incubation
time of about 3 to 14 days, and the presence of many asymptom-
atic and presymptomatic SARS-CoV-2–infected individuals pro-
ducing sufficient amounts of virus for human-to-human
transmission.7-9 Thus, SARS-CoV-2 infection is frequently
unrecognized.
When symptomatic, COVID-19 can range from a mild flu-like
illness in about 81% of affected patients to a severe and critical
disease in about 14% and 5% of affected patients, respec-
tively.10-12 Mild COVID-19 is characterized by fatigue, fever,
sore throat, cough, and mild pneumonia. Severe disease features
dyspnea, hypoxia, and radiographic evidence of lung involvement
of 50% or more, and critical COVID-19 results in acute respira-
tory distress syndrome (ARDS) with respiratory failure, multior-
gan dysfunction, and shock. The World Health Organization
proposed a classification of symptomatic COVID-19 into (1)
mild illness, (2) mild pneumonia, (3) severe pneumonia, (4)
ARDS (based on the Berlin definition of ARDS),13 and (5) sepsis
and septic shock.14
Human angiotensin-converting enzyme 2 (ACE2) serves as a
cell entry receptor for SARS-CoV-2. Pneumocytes and other host
cells expressing ACE2 are therefore particularly susceptible to
infection by SARS-CoV-2. Mechanistically, SARS-CoV-2 binds
toACE2 via the receptor-binding domain (RBD) of the S1 subunit
of its surface spike (S) glycoprotein.3,15 Thus, humoral immunity
targeting the S protein could interfere with SARS-CoV-2 infec-
tion, as evidenced from serologic studies.16,17
As with other coronaviruses, symptomatic SARS-CoV-2 dis-
ease causes an acute infection with activation of the innate and
adaptive immune systems. The former leads to the release of
several proinflammatory cytokines, including IL-6. Conversely,
other antiviral cytokines, such as the type I and III interferon
pathways, are hampered by coronaviruses, including SARS-CoV
and SARS-CoV-2.18-20 Subsequently, B cells and T cells become
activated, resulting in the production of SARS-CoV-2–specific
antibodies, comprising IgM, IgA, and IgG.21 Whereas
coronavirus-specific IgM production is transient and leads to iso-
type switch to IgA and IgG,22 these latter antibody subtypes can
persist for extended periods in the serum and in nasal fluids.23
Whether SARS-CoV-2–specific IgG antibodies are correlated
with virus control is a matter of intense discussion.16,17,24,25
Unlike the internal nucleocapsid protein of SARS-CoV-2,
which shares about 90% amino acid sequence homology with
the nucleocapsid protein of SARS-CoV, the S1 subunit shares
only 64% amino acid sequence homology and shows limited
homology with other human coronaviruses, such as 229E, NL63,
OC43, and HKU1, which use different viral entry receptors.3,26
Thus, antibodies generated to previous coronavirus infections
are unlikely to cross-react with the S1 protein of SARS-CoV-2
and should therefore not significantly account for any seroreactiv-
ity toward the S1 subunit.26
Despite intensive research efforts, several determinants of
SARS-CoV-2–specific antibody production remain ill-defined,
such as its relation to COVID-19 severity, disease duration,
patient age, and comorbidities. There is also a paucity of
knowledge on SARS-CoV-2–specific IgA and IgG antibodies at
mucosal sites and how their titers are correlated with COVID-19
parameters. And finally, it is unclear whether tissue-associated
IgA and IgG secretion, rather than their systemic production,
might be evident in SARS-CoV-2–exposed individuals experi-
encing mild disease.
Abbreviations used
ACE2: Angiotensin-converting enzyme 2
ARDS: Acute respiratory distress syndrome
COVID-19: Coronavirus disease 2019
Ct: Cycle threshold
ECD: Extracellular domain
HCW: Health care worker
IQR: Interquartile range
RBD: Receptor-binding domain
RT-qPCR: Reverse-transcriptase quantitative PCR
S: Spike
SARS-CoV: Severe acute respiratory syndrome coronavirus
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
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METHODS
Human subjects and patient characteristics
Following written informed consent, patients and health care workers
(HCWs) were recruited for sampling of blood and mucosal secretions. We
studied 2 cohorts: (1) patients with reverse-transcriptase quantitative PCR
(RT-qPCR)-confirmed SARS-CoV-2 infection (n 5 64; median age 59.5
years) with mild versus severe COVID-19 and (2) HCWs (referred to as the
HCW cohort; n5 109; median age 36 years) with or without symptoms, who
tested negative or positive for SARS-CoV-2 by RT-qPCR. HCWs included
employees of University Hospital Zurich belonging to all professional groups,
both with and without patient contact. Exposure was defined as contact with a
patient with RT-qPCR–confirmed COVID-19 without adequate safety mea-
sures.27 Because of preexisting comorbidities, 6 patients were under stable
immunosuppressive treatment at the time of inclusion (Table I); conversely,
patients receiving B-cell–depleting agents, such as rituximab,28 were
excluded from our study. For longitudinal analyses of serum and mucosal
SARS-CoV-2–specific antibody responses, 2 subjects with mild COVID-19
were sampled repeatedly during the course of their disease. Our patients
with COVID-19 were classified according to the World Health Organization
criteria14 as (1) those with mild COVID-19, comprising mild illness and
mild pneumonia or (b) those with severe COVID-19, including severe pneu-
monia and ARDS. Our cohort did not contain any patients with sepsis or septic
shock. The study was approved by the Cantonal Ethics Committee of Zurich
(BASEC 2016-01440 and 2020-00363).
Collection of serum, tears, nasal fluid, and saliva
A subgroup of members of the HCW cohort (referred to as the HCW
mucosal subgroup [n 5 33]) volunteered to be sampled for blood, as well as
(simultaneously) for tears, nasal fluid, and saliva. Venous blood samples were
collected in BD Vacutainer CAT serum tubes (Becton Dickinson, Franklin
Lakes, NJ). Tears were sampled by using filter paper produced for Schirmer
tear tests (HS Clement Clarke Ophtalmic, Harlow, United Kingdom). Nasal
fluids were collected by inserting a dry soft tissue into the nasal cavities for 5
minutes (Vostra, Aachen, Germany). Unstimulated saliva was collected for 5
minutes.
IgA and IgG immunoassays
A commercial ELISA specific for the S1 protein of SARS-CoV-2 was used
according to manufacturer’s instructions (SARS-CoV-2 IgA and IgG immu-
noassay, Euroimmun, L€ubeck, Germany) and validated by using serum
samples from hospitalized patients with confirmed COVID-19 as positive
controls and serum samples collected before the COVID-19 pandemic as
negative controls. The results showed a specificity for anti-S1 IgA greater than
95% and for anti-S1 IgG greater than 99%, which is in accordance with
recently published data.29 Serum samples were analyzed at a 1:100 dilution,
and mucosal samples were analyzed at a 1:5 dilution (with 0.9% NaCl). For
serum IgA, OD ratios of 1.1 to 2.0 were considered borderline positive and
values higher than 2.0 were considered positive. For serum IgG, OD ratios
of 0.8 to 1.1 were considered borderline positive and values greater than 1.1
were considered positive.
Furthermore, we assessed the samples from theHCWmucosal subgroup by
using an in-house immunoassay for IgA and IgG against S protein
extracellular domain (ECD), RBD, and nucleocapsid protein.30Mucosal sam-
ples were prediluted 1:2 in sample buffer (PBS Tween-20, 0.1%, and 1%
milk), and serum was prediluted 1:20 in sample buffer and transferred to
antigen-coated 1536-well assay plates by using acoustic dispensing
TABLE I. Demographic and clinical characteristics of the patient cohort
Characteristic Patients with mild COVID-19 (n 5 26) Patients with severe COVID-19 (n 5 38) Total (n 5 64) P value
Age (y), median (IQR) 46.0 (31.50-48.50) 67.5 (59.0-79.0) 59.5 (42.75-75.25) <.0001
Sex (male/female) 11/15 24/14 35/29 .1282
COVID-19 disease severity, no. (%)*
Mild illness 17 (65.4) — 17 (26.6) —
Mild pneumonia 9 (34.6) — 9 (14.1) —
Severe pneumonia — 20 (52.6) 20 (31.3) —
Mild ARDS — 7 (18.4) 7 (10.9) —
Moderate ARDS — 7 (18.4) 7 (10.9) —
Severe ARDS — 4 (10.5) 4 (6.3) —
Level of care at blood sampling time point, no. (%)
Outpatient 14 (53.8) — 14 (21.9) <.0001
Hospitalized 12 (46.2) 38 (100) 50 (78.1) <.0001
Comorbidity, no. (%)
Hypertension 6 (23.1) 22 (57.9) 28 (43.8) .0098
Diabetes 4 (15.4) 12 (31.6) 16 (25) .2393
Heart disease 2 (7.7) 17 (44.7) 19 (29.7) .0018
Cerebrovascular disease 1 (3.8) 4 (10.5) 5 (7.8) .6404
Lung disease 3 (11.5) 6 (15.8) 9 (14.1) .7275
Kidney disease 6 (23.1) 10 (26.3) 16 (25) >.9999
Malignancy — 4 (10.5) 4 (6.3) .1397
Systemic immunosuppression 2 (7.7) 4 (10.5) 6 (9.4) >.9999
Immunosuppression, no. (%)
Glucocorticoids 2 (7.7) 4 (10.5) 6 (9.4) >.9999
Mycophenolate mofetil 1 (3.8) — 1 (1.6) .4062
Calcineurin inhibitors 1 (3.8) 1 (2.6) 2 (3.1) >.9999
Azathioprin 1 (3.8) 2 (5.3) 3 (4.7) >.9999
Leflunomide 1 (3.8) — 1 (1.6) .4062
Mesalazine 1 (3.8) — 1 (1.6) .4062
IQR, Interquartile range.
Patients were divided into those with mild versus those with severe COVID-19. Disease severity was defined according to the World Health Organization classification.14 Categoric
values between mild and severe COVID-19 were compared by using the Fisher exact test, and continuous variables were compared by using the nonparametric Wilcoxon test.
*COVID-19 severity at blood sampling according to World Health Organization guidelines.14
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FIG 1. Influence ofCOVID-19 severity, disease duration, andpatient age onSARS-CoV-2–specific serum IgA and
IgG titers.A, Comparison of SARS-CoV-2 S protein subunit S1-specific serum IgA and IgG titers (OD ratio) in pa-
tients withmild (n5 26) versus severe COVID-19 (n5 38). The average times between reported symptom onset
andsamplecollectionwere13.5days(median9days) inpatientswithmildcasesand20.2days (median15.5days)
in patientswith severe cases.B,Generalized additivemodeling of S1-specific IgA and IgG serum titers as a func-
tion of days between reported symptomonset and sample collection in patientswithmild (n5 26) versus severe
COVID-19(n538).Dashedlines indicatebordersbetweenpositiveandborderlineornegativeserumvaluesofS1-
specific IgA (top) and IgG (bottom). C, Linear modeling of S1-specific IgA and IgG serum titers as a function of
patient age in patients withmild (n5 26) versus severe cases (n5 38). P values and adjustedR2 (R2adj) of linear
and generalized additive models were computed by using logarithmized IgA/IgG titers.
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technology (ECHO555, Labcyte, San Jose, Calif) with serial dilutions ranging
from 1:5 to 1:640 (mucosal samples) and from 1:50 to 1:6400 (serum sam-
ples). ODsweremeasured at 450 nm in amultimode plate reader (Elmer EnVi-
sion, Perkin, Rodgau, Germany), followed by fitting with a logistic regression
and determination of the inflection point of the sigmoidal curve (–log(EC50)).
Negative values were depicted as 0.
RT-qPCR
Nasopharyngeal swabs were subjected to RT-qPCR by using the TaqMan
SARS-CoV-2 Assay Kit v2 (Thermo Fischer, Waltham, Mass), the 2019-
nCoV CDC qPCR Probe Assay (2019-nCov CDC EUA Kit; Integrated DNA
Technologies, Inc, Coralville, Iowa), or the Roche cobas SARS-CoV-2 Test
CE-IVD (Roche, Basel, Switzerland) according to the manufacturers’ in-
structions. The cycle threshold (Ct) values for the different SARS-CoV-2 PCR
targets were compounded and reported as averages.
SARS-CoV-2 microneutralization assay
Serum, nasal fluid, and tear fluid samples were diluted in Dulbecco modified
Eagle medium plus 2%FCS, 20 mMHEPES, and 0.05%NaHCO3. Twofold se-
rial dilutions were mixed with an equal volume of SARS-CoV-2 viral solution
(350 plaque-forming units/50 mL), resulting in final sample dilutions ranging
from 1:10 to 1:40 for sera and 1:5 to 1:20 for mucosal fluid samples. The
serum-virus mix was incubated for 1 hour at room temperature and dispersed
on 96-well plates containing a semiconfluent VeroE6 monolayer. The plates
were incubated for 20 hours at 378C in a humidified atmosphere with 5% CO2
before fixation and fluorescent staining with a SARS-CoV nucleocapsid
protein–specific antibody (catalog no. 200-401-A50, Biomol, Hamburg, Ger-
many). The assay was evaluated by fluorescence microscopy, with plaque
reduction less than 50% interpreted as absent, from 50% to 80% interpreted
as partial, and from 80% to 100% interpreted as full neutralization; all results
were compared with a control without patient serum or mucosal fluid.
Statistics
Descriptive statistics for the cohort of patients (stratified according to mild
versus severe disease) and the HCW cohort are presented as median and
interquartile ranges for continuous variables, and as numbers and percentages
of the total for categoric variables. For the comparison of location parameters
in 2 independent groups, the Wilcoxon rank sum test was used in a version
accounting for ties.31 For comparison of more than 2 independent groups, the
nonparametric Kruskal-Wallis test was used. Multiple linear regression
models were used to quantify the association between log-transformed IgA
and IgG titers as outcomes as well as a set of predefined independent variables.
These included disease severity, age, duration of symptoms (days), and patient
comorbidities. Generalized additive models were used to evaluate potential
nonlinear relationships of disease duration with the 2 outcomes, as already
described. The Wilcoxon test was used to test for differences between 2
continuous variables in the tables, and P values were adjusted by using the
Holm method. The Fisher exact test was used for comparing 2 categoric vari-
ables, and the chi-square test was used for comparing 3 categoric variables.
Nonparametric Spearman correlations were used for the comparison between
different immunoassays.
Statistical analyses were performed with R software (version 3.6.1) and by
using the packages coin and mgcv. GraphPad Prism software (GraphPad
Software, Inc, La Jolla, Calif) was used for visualization. P values in the pa-
tient cohort were adjusted for multiple testing by using the method proposed
by Benjamini-Hochberg.32 Adjusted P values were considered statistically
significant if smaller than the significance level of a 5 0.05. In the HCW
mucosal subgroup, evidence was quantified on a continuous scale, and the re-
sults were considered exploratory.
RESULTS
COVID-19 severity, disease duration, and patient
age influence SARS-CoV-2–specific serum IgA and
IgG secretion
Serum samples from 64 patients with RT-qPCR–confirmed
mild (n 5 26) and severe (n 5 38) cases of COVID-19 (Table I)
were assessed for IgA and IgG antibodies toward the SARS-CoV-
2 S1 protein by using highly specific immunoassays. The mean
periods between reported symptom onset and serum collection
were 13.5 days (median 9 days) in the group of patients with
mild COVID-19 and 20.2 days (median 15.5 days) in the group
with severe COVID-19, respectively (see Fig E1,A in this article’s
Online Repository at www.jacionline.org). On average, patients
with severe disease had higher serum titers of S1-specific IgA
(P < .0001) and IgG (P < .0001) than did patients with mild
COVID-19 (Fig 1, A). In patients with mild COVID-19, serum ti-
ters of S1-specific IgA increased slightly (P <.0001) as a function
of time from serum sampling to symptom onset (Fig 1, B). Like-
wise, serum titers of S1-specific IgG increased moderately (P 5
.002) in patients with mild COVID-19 (Fig 1, B). These antibody
responses revealed no significant pattern associated with patient
age (P 5.15 for IgA and P 5.28 for IgG) (Fig 1, C); sex (see
Fig E1, B and C); preexisting comorbidities, including hyperten-
sion, diabetes mellitus, heart disease, cerebrovascular disease,
lung disease, and kidney disease; or immunosuppressive treat-
ment. In patients with a history of solid cancer, lower S1-
specific IgA titers were detectable (Table II).
On average, positive S1-specific serum IgA titers became
evident in patients with mild COVID-19 10 days after symptom
TABLE II. Linear models for prediction of IgA and IgG serum
titers
Serum titer Coefficient 95% CI P value
SARS-CoV-2–specific IgA serum titer
Intercept –0.90 –1.92 to 0.12 .083
Severe disease 1.35 0.74 to 1.96 <.0001
Days 0.053 0.03 to 0.08 <.0001
Age 0.011 –0.01 to 0.03 .31
Hypertension 0.27 –0.48 to 1.02 .47
Diabetes –0.23 –0.89 to 0.42 .48
Heart disease –0.18 –0.87 to 0.52 .61
Lung disease –0.18 –0.95 to 0.59 .63
Malignancy –1.77 –2.87 to –0.67 .002
Cerebrovascular disease 0.24 –0.81 to 1.30 .64
Kidney disease –0.17 –0.88 to 0.53 .63
Immunosuppression –0.44 –1.46 to 0.57 .39
SARS-CoV-2–specific IgG serum titer
Intercept –1.66 –2.81 to –0.51 .005
Severe disease 1.42 0.73 to 2.11 .0001
Days 0.07 0.04 to 0.10 <.0001
Age 0.0012 –0.02 to 0.03 .92
Hypertension 0.41 –0.43 to 1.26 .33
Diabetes –0.19 –0.92 to 0.55 .62
Heart disease –0.13 –0.91 to 0.65 .73
Lung disease –0.31 –1.18 to 0.55 .47
Malignancy –0.89 –2.13 to 0.34 .15
Cerebrovascular disease –0.44 –1.63 to 0.75 .46
Kidney disease 0.21 –0.58 to 1.01 .59
Immunosuppression –0.76 –1.90 to 0.39 .19
Multiple linear model of S1 protein–specific IgA serum titers (logarithmized) and IgG
serum titers (logarithmized) as a function of disease severity (mild versus severe),
days since onset of symptoms, patient age, presence of comorbidities (hypertension,
diabetes mellitus, heart disease, cerebrovascular disease, lung disease, kidney disease,
and malignancy), and immunosuppressive treatment (n 5 64).
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onset (Fig 1, B). S1-specific serum IgA titers peaked in samples
drawn at around 3 weeks from symptom onset, whereas in sub-
jects tested later S1-specific serum IgA tended to be lower. As
for S1-specific serum IgG concentrations, they remained negative
or reached positive values in patients with mild COVID-19
around 12 to 14 days after symptom onset (Fig 1, B).
In stark contrast to those with mild cases, patients with severe
COVID-19 showed a strong correlation of serum titers of S1-
specific IgAwith disease duration (P 5 .0008), with the correla-
tion being even more pronounced for serum titers of S1-specific
IgG (P < .0001) (Fig 1, B). On average, these antibody responses
became positive in samples obtained on day 3 or 4 for IgA and day
4 or 5 for IgG, and they appeared to be independent of patient age
(P5 .76 for IgA and P5 .76 for IgG), sex, and comorbidities (Fig
1, B and C, Table II, and see Fig E1, B and C).
When patients were grouped according to level of care, in those
with mild cases of COVID-19 we observed that S1-specific serum
IgA titers did not show any discernible pattern, whereas S1-
specific serum IgG titers were higher in hospitalized patients than
in patients treated as outpatients (Fig 2,A). Thus, we next assessed
disease severity, and as expected, younger patients tended to have
milder disease, whereas older patients had more severe manifes-
tations (see Fig E2 in this article’s Online Repository at www.
jacionline.org). There was no time-dependent pattern visible for
S1-specific serum IgA titer, whereas S1-specific serum IgG titers
showed a stronger increase over time in patients with mild pneu-
monia versus in those with mild illness (Fig 2, B). Strikingly, very
high titers (>25 OD ratio) of SARS-CoV-2–specific serum IgA,
but not serum IgG, were correlated with severe ARDS (Fig 2, B
and see Fig E3 in this article’s Online Repository at www.
jacionline.org). In a multiple linear model on all patients, there
was strong evidence for an association between severe disease,
days after symptom onset, and increased S1-specific serum IgA
and IgG responses. Immunosuppressive therapy was not associ-
ated with decreased S1-specific serum IgG titers (Table II).
In summary, disease severity appeared to influence S1-specific
serum IgA and IgG titers, and S1-specific IgA responses might
occur transiently in patients with mild disease. To evaluate this
latter hypothesis, we conducted a longitudinal study in 2 selected
patients with mild COVID-19, as presented in the next section.
S1-specific antibody responses can be transient and
delayed in patients with mild COVID-19
We followed up 2 adults (a 42-year-old woman and a 42-year
old man living together as a couple) with mild, RT-qPCR–
confirmed SARS-CoV-2 infection. He (patient COV2-A0013)
developed fatigue and cough from day 0 onward, followed by
fever on day 1 and dysosmia on days 9 to 16. She (patient COV2-
A0014) showed signs of fatigue and sore throat from day
0 onward, fever between days 2 and 5, and cough on day 3 (Fig
3, A).
The RT-qPCR Ct values at detection were low on days 1 to 20
for patient COV2-A0013 and on day 7 for patient COV2-A0014,
indicating the presence of high amounts of SARS-CoV-2 RNA in
their nasal swabs (Fig 3, B). On day 30 for patient COV2-A0013
and from day 17 onward for patient COV2-A0014, the Ct values
increased to 40 and higher, thus indicating that the amount of vi-
rus RNA had dropped below the detection limit (Fig 3, B).
Patient COV2-A0013 showed S1-specific serum IgA titers that
were negative on day 7; rose to borderline values on day 10;
became positive on day 14 at a titer of 3.8 OD ratio, where they
FIG 2. S protein–specific serum antibodies compared with level of care and disease severity. A, Level of pa-
tient care at the time of blood sampling, visualized in the generalized additive models of S1-specific IgA and
IgG serum titers as a function of days between sampling and reported symptom onset in patients with mild
cases of COVID-19 (n 5 26). Patients with severe cases were all hospitalized and are thus not depicted. B,
Disease severity at the time of blood sampling, visualized in the generalized additive models of S1-
specific IgA and IgG serum titers as a function of days between sampling and reported symptom onset.
Comparison of patients with mild (n 5 26) versus severe cases (n 5 38).
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remained on day 20; and further increased to a titer of 8.5 OD ratio
on day 30. His S1-specific serum IgG titers remained negative on
days 7 to 14, became borderline positive on day 20, and became
clearly positive at an OD ratio of 4.5 on day 30 (Fig 3, C).
Conversely, the S1-specific serum IgA titers in patient COV2-
A0014 were borderline on day 4 and became positive on days 7
and 11, followed by a drop to borderline values on days 17 and
28. Her S1-specific serum IgG titers were negative on days 4 to
7, became borderline on day 11 andweakly positive at anOD ratio
of 1.1 on day 17, and remained weakly positive at an OD ratio of
1.8 on day 28 (Fig 3, C). We compared these results with those of
longitudinal analyses of S1-specific serum IgA and IgG values in
FIG 3. Longitudinal study of 2 mild cases of COVID-19. A, Time of reporting of indicated symptoms in 2 pa-
tients with mild COVID-19, including a 42-year old male (COV2-A0013 [left panels]) and a 42-year old female
(COV2-A0014 [right panels]). B, Ct values of SARS-CoV-2 RT-qPCR assay performed on nasopharyngeal
swabs. C, S1-specific IgA and IgG serum titers analyzed on different days after symptom onset. Data are
shown on a longitudinal axis. Dashed lines indicate cutoffs for positive, borderline, and negative serum
values of S1-specific IgA (top) and IgG (bottom), with the gray shaded area highlighting the borderline
values.
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2 different situations. In asymptomatic controls, S1-specific
serum IgA and IgG titers remained negative throughout the period
of assessment, whereas in patients with severe COVID-19 both
antibody responses increased after day 4 to 5 and were markedly
elevated on day 14 to 15 (see Fig E4 in this article’s Online Repos-
itory at www.jacionline.org).
These longitudinal data in patients with mild COVID-19
demonstrate that S1-specific serum IgA production can be
transient, whereas S1-specific serum IgG production occurs late
and is correlated with the severity of clinical symptoms.
Some seronegative HCWs show SARS-CoV-2–
specific IgA at mucosal sites
Having observed that in patients with mild COVID-19, S1-
specific serum IgA and IgG production can be transient, delayed,
or even absent, we assessed serum S1-specific antibody responses
in a well-defined cohort of HCWs (n 5 109; the HCW cohort).
These HCWs either did or did not have clinical symptoms
suggestive of COVID-19, and on the basis of respiratory
secretions tested by RT-qPCR, they were either negative or
positive for SARS-CoV-2. We grouped them as follows (Fig 4):
(1) asymptomatic, RT-qPCR–negative, with a recent history of
SARS-CoV-2 exposure (n 5 17); (2) symptomatic, RT-qPCR–
negative (n 5 71); and (3) symptomatic, RT-qPCR–positive
(n 5 21).
The asymptomatic/PCR-negative group contained very few
S1-specific serum IgA-positive subjects and no IgG-positive
subjects (Fig 5, A). Conversely, there were 4 of 71 participants
(6%) with positive IgA and IgG values found in the
symptomatic/PCR-negative group, which likely represented indi-
viduals who had had a mild SARS-CoV-2 infection (Fig 5, A). As
expected, the symptomatic/PCR-positive group contained more
seropositive individuals, with 8 of 21 subjects (38%) having pos-
itive IgA and IgG titers for S1 of SARS-CoV-2 at the time of sam-
pling (Fig 5, A).
To investigate S1-specific IgA and IgG titers at mucosal sites,
we analyzed tears, nasal fluids, and saliva in a subset of the HCW
cohort (ie, the HCW mucosal subgroup) (Fig 4). This subgroup
also recorded self-reported clinical symptoms (Tables III and
IV). When the symptomatic/PCR-positive members of the
HCW mucosal subgroup were assessed, a clear correlation was
evident between positivity of S1-specific IgA and IgG in serum
(Fig 5, B) with the corresponding values in nasal secretions (Fig
5, C). Thus, for S1-specific IgG, symptomatic/PCR-positive
members with positive serum titers also showed elevated titers
of S1-specific IgG in their nasal secretions (Fig 5, B and C),
possibly indicating transfer of S1-specific IgG from serum to
the nasal mucosa. Conversely, the relationship of serum versus
nasal fluid in symptomatic/PCR-positive members was more var-
iable for S1-specific IgA (Fig 5, B and C).
To further investigate these findings, we adapted and used our 2
SARS-CoV-2 S protein–specific immunoassays (Figs E5 and E6)
to assess the subjects in the HCW mucosal subgroup who tested
negative for SARS-CoV-2–specific IgA or IgG in their serum.
First, we ruled out an influence of time of sampling or total
amount of detectable IgA and IgG in our samples. The mean
time of sampling since symptom onset was 26.5 days for both
FIG 4. Flowchart showing characterization of the HCW cohort. We grouped our HCW cohort (n 5 109) as
follows: (1) asymptomatic, PCR-negative (n5 17) reporting exposure (see the Methods section) to a patient
with COVID-19 11 to 24 days before sampling; (2) symptomatic, PCR-negative (n5 71); and (3) symptomatic,
PCR-positive (n 5 21). All HCWs were analyzed for SARS-CoV-2 S1–specific serum IgA and IgG values. In a
subgroup (the HCWmucosal subgroup), tears, nasal fluid, saliva, and serumwere collected simultaneously.
Self-reported symptoms of each participant of the HCW mucosal subgroup were recorded. The 33 HCWs in
the HCW mucosal subgroup were grouped in the same way as the HCW cohort: (1) asymptomatic, PCR-
negative (n 5 9); (2) symptomatic, PCR-negative (n 5 13), sampled on average 26.5 days after symptom
onset; and (3) symptomatic, PCR-positive (n 5 11), sampled on average 26.5 days after symptom onset.
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the symptomatic/PCR-negative and symptomatic/PCR-positive
groups of the HCW mucosal subgroup, whereas the
asymptomatic/PCR-negative group was tested 11 days or more
after exposure. Total IgA and IgG titers were comparable in the
serum samples as well as in the tear, nasal fluid, and saliva sam-
ples from all 3 groups of participants (see Fig E7 in this article’s
Online Repository at www.jacionline.org). Notably, whereas total
IgG titers were measurable in nasal fluids, they were very low in
tear fluid and saliva (see Fig E7). Analyzing S protein–specific
IgA and IgG in our mucosal samples, we observed a reliable cor-
relation between our 2 immunoassays for serum IgA and IgG, as
well as for tear and nasal fluid IgA, whereas the other measure-
ments were less consistent and were thus not considered for our
conclusions (see Fig E6 in this article’s Online Repository at
www.jacionline.org).
Interestingly, we were able to detect S protein–specific IgA in
the mucosal samples from several subjects in the absence of
seropositivity. Analyzing individual participants, we found that
subjects COV2-M0033, COV2-M0061, and COV2-M0103
showed high S1-specific, ECD-specific, and RBD-specific IgA
values in their nasal fluids, whereas the total IgA values were
average in nasal fluids of these individuals (Fig 5,D-F and see Fig
E7). Moreover, the nasal fluid of subject COV2-M0015 contained
high S1-specific and RBD-specific IgA values, in the presence of
average total IgA values (Fig 5, D-F and see Fig E7). When
their tear fluid was measured, subjects COV2-M0015 and
COV2-M0033 presented with high S1-specific, ECD-specific,
or RBD-specific IgAvalues (Fig 5,G-I). Additionally, a few other
individuals also had detectable S protein–specific IgG in their
nasal fluid despite being IgG seronegative (Fig 5, D-F). Notably,
some mucosal samples showed comparable neutralizing capacity
to serum in an in vitro neutralization assay of viable SARS-CoV-2
(see Fig E8 in this article’s Online Repository at www.jacionline.
org). These findings further supported our detection of humoral
immune reponses at mucosal sites in patients with mild
COVID-19 in the absence of serum antibodies toward SARS-
CoV-2.
In contrast to total IgA titers, when we assessed S protein–
specific IgA values in nasal fluid versus age in seronegative
HCWs, we found an inverse correlation (R2adj 5 0.153; P 5
.037). The same analysis with S protein–specific IgA titers in
serum versus age, however, did not reveal a correlation (P 5
.58) (Fig 5, J-L). Interestingly, the longitudinal subject with a
short disease duration (COV2-A0014), transient S protein–
specific IgA, and delayed IgG production also had high titers of
S protein–specific IgA in her nasal fluid (see Fig E9 in this arti-
cle’s Online Repository at www.jacioniline.org).
Collectively, in 15% to 20% of S protein–seronegative in-
dividuals in our cohort, we detected S protein–specific IgA
antibodies at several mucosal sites. Furthermore, mucosal S
protein–specific IgA titers were inversely correlated with patient
age, suggesting increased mucosal antibody responses in younger
SARS-CoV-2–exposed individuals.
DISCUSSION
In individuals with severe COVID-19, we found that SARS-
CoV-2 S protein–specific serum IgA and IgG titers became
positive in samples obtained on average 3 to 5 days after symptom
onset, which is in agreement with the findings of earlier
publications.16 These antibody responses showed a strong
correlation with disease duration, but they were independent of
patient age, sex, and most preexisting comorbidities. Very high
serum titers of S protein–specific IgA, but not IgG, were corre-
lated with severe ARDS, thus warranting further studies evalu-
ating the role of IgA in SARS-CoV-2-associated severe ARDS.
Conversely, in patients with mild SARS-CoV-2 infection, S
protein–specific serum IgA production was transient, delayed, or
even absent and accompanied by an S protein–specific serum IgG
response that occurred late or remained negative. Interestingly,
however, we found evidence of S protein–specific IgA and IgG at
mucosal sites of individuals with mild COVID-19. There,
mucosal S protein–specific IgG titers appeared to mirror the
systemic (ie, serum) titers of these antibodies. Mucosal S protein–
specific IgA titers, however, were even detectable at several
mucosal sites of about 15% to 20% of S protein–seronegative
individuals in our cohort. Interestingly, mucosal S protein–
specific IgA titers were correlated inversely with patient age.
We think that these findings suggest a model according towhich
the extent and duration of SARS-CoV-2–related clinical symp-
toms, which are likely correlated with virus replication, dictate the
level of virus-specific humoral immunity. This hypothesis is
consistent with the findings of previous publications demonstrating
that themagnitude of the humoral response toward SARS-CoV-2 is
dependent on the duration and magnitude of viral antigen
exposure.33,34 Low antigen exposure will elicit mucosal IgA-
mediated responses, which can be accompanied by systemic IgA
production; however, systemic virus-specific IgA responses can
also be absent, transient, or delayed. This type of ‘‘mucosal IgA’’
antibody response seemed to be particularly prevalent in younger
individuals with mild SARS-CoV-2 infection without evidence
of pneumonia. These projected longitudinal relationships from
cross-sectional evaluations need confirmation in longitudinal
studies. Notably, of the 2 subjects in our longitudinal study, patient
COV2-A0014 showed milder and shorter-lasting clinical symp-
toms and more rapid virus clearance, which was associated with
transient S protein–specific IgA and delayed IgG production, but
high titers of S protein–specific IgA in her nasal fluid.
These data might be a reflection of increased mucosal
immunity in the young or decreased mucosal immunity in the
old.35 Along these lines, previous data on coronavirus seropreva-
lence of HKU1-specific IgG showed an absence of systemic
HKU1-specific antibodies in individuals younger than 20 years
of age, with increasing seroprevalence with increasing age.36
Extrapolating this model to also include children and infants, it
is conceivable that children and infants have primed mucosal
innate and IgA antibody responses on account of their frequent
upper respiratory tract infections and therefore respond preferen-
tially in this manner to SARS-CoV-2 infection. This hypothesis
might also explain why children rarely present with symptomatic
SARS-CoV-2 infection. Looking at the other end of the age sprec-
trum, previous studies have shown that the kinetics and strength of
antiviral immune responses, including T-cell activation and pro-
liferation, become slower with increasing age.37,38 The elucida-
tion of these questions and the confirmation of our findings will
require larger studies. However, because of the transient nature
of S protein–specific antibody responses in oligosymptomatic pa-
tients, reliance on measurement of SARS-CoV-2–specific serum
IgA and IgG titers in asymptomatic patients might underestimate
the percentage of individuals who have experienced this corona-
virus infection and thus, may be deceiving when estimating the
epidemic spread of SARS-CoV-2. Our data suggest that, in
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FIG 5. Analysis of SARS-CoV-2 S protein–specific IgA and IgG responses in serum and mucosal fluids. A, S
protein–specific IgA (top) and IgG (bottom) serum titers in the HCW cohort (n5 109). Dashed lines indicate bor-
ders between positive (red), borderline (gray), and negative (blue) values, with the gray-shaded area showing
borderline values. B and C, S protein–specific IgA (top) and IgG (bottom) serum (B) and nasal fluid (C) titers
of symptomatic, PCR-positive (Symp/PCR1) individuals (n 5 11) in the HCW mucosal subgroup. Comparison
of HCWs with negative, borderline, and positive values. D-F, S protein–specific IgA (top) and IgG (bottom) titers
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addition to measurement of serum, measurement of SARS-CoV-
2–specific mucosal IgA should be considered.
With increased SARS-CoV-2–related clinical symptoms and
hence antigen exposure, we observed a ‘‘systemic IgA and IgG’’
type of antibody response characterized by S protein–specific IgA
that may be transient or delayed and the presence of S protein–
specific IgG. With even further increasing clinical severity, we
found high to very high serum IgA and high IgG responses in
patients with severe cases andARDS. Thus, our findings suggest 4
grades of antibody responses dependent on COVID-19 severity
with (1) oligosymptomatic disease and mucosal antibody re-
sponses in the absence of systemic antibody production; (2) mild-
to-moderate disease and transient or delayed systemic IgA and
IgG production; (3) patients with severe COVID-19 with high
serum IgA and high IgG responses; and (4) patients with very
severe cases of COVID-19, including severe ARDS, with very
high serum IgA and high IgG titers.
Whether these S protein–specific antibody responses confer
immunity to a secondary infectionwith SARS-CoV-2 is amatter of
intense debate. Previous publications indicated that S protein–
specific serum IgG antibodies are correlated with virus neutrali-
zation in vitro,16,17,39 although some publications have questioned
the efficacy of neutralization by these antibody responses.25 Our
neutralization data showed a correlation between SARS-CoV-2–
neutralizing activity and detectable S protein–specific IgA and
IgG in both serum andmucosal fluids, suggesting that the observed
humoral responses could be protective. On the basis of correlative
data from the SARS-CoV outbreak and preclinical SARS-CoV
infection models,40 a contribution of the humoral immune
response to immune pathology has been discussed,41,42 potentially
TABLE III. Demographic characterstics of the HCW cohort included in the S protein–specific IgA and IgG serology study
Characteristic
Asymptomatic/
PCR-negative (n 5 17)
Symptomatic/
PCR-negative (n 5 71)
Symptomatic/
PCR-positive (n 5 21) Total (n 5 109) P value
Median age (y), median (IQR) 39 (34-44) 36 (30-41) 38 (30-48) 36 (30-43) .4156
Sex (male/female) 6/11 16/55 3/18 25/84 .3066




PCR-negative (n 5 9)
Symptomatic/
PCR-negative (n 5 13)
Symptomatic/
PCR-positive (n 5 11) Total (n 5 33) P value
Median age (y), median (IQR) 38 (36-44) 40 (32-49) 38 (30-42) 39 (31-43) .8
Sex (male/female) 4/5 6/7 3/8 13/20 .5999
Reported symptoms, no. (%)
Fatigue — 6 (46.2) 7 (63.6) 13 (39.4) .4442
Body temperature >38.08C — 4 (30.8) 1 (9.1) 5 (15.2) .3271
Feeling feverish — 6 (46.2) 4 (36.4) 10 (30.3) .6968
Chills — 1 (7.7) 2 (18.2) 3 (9.1) .5761
Shivering — 3 (23.1) 4 (36.4) 7 (21.2) .6591
Body aches — 8 (61.5) 8 (72.7) 16 (48.5) .6792
Back pain — 5 (38.5) 4 (36.4) 9 (27.3) >.999
Cough — 5 (38.5) 6 (54.5) 11 (33.3) .6824
Dyspnea — 2 (15.4) 4 (36.4) 6 (18.2) .3572
Pleuritis — 3 (23.1) 4 (36.4) 7 (21.2) .6591
Sore throat — 11 (84.6) 6 (54.5) 17 (51.5) .1819
Coryza — 7 (53.8) 6 (54.5) 13 (39.4) >.999
Hoarseness — 5 (38.5) 4 (36.4) 9 (27.3) >.999
Anosmia/dysosmia — 2 (15.4) 8 (72.7) 10 (30.3) .0111
Diarrhea — 5 (38.5) 2 (18.2) 7 (21.2) .3864
Nausea — 3 (23.1) 3 (27.3) 6 (18.2) >.999
Conjunctivitis — 2 (15.4) — 2 (6.1) .4819
Categoric values were compared by using the Fisher exact test or chi-square if more than 2 groups were being compared. Continuous variables were compared by using the
Kruskal-Wallis test.
in nasal fluid, including S1-specific (D), SARS-CoV-2 S protein extracellular domain (ECD)-specific (E), and S1
protein RBD–specific IgA and IgG (F) of S1 protein–seronegative individuals in the HCW mucosal subgroup.
Comparison of asymptomatic, PCR-negative (Asymp/PCR–), symptomatic, PCR-negative (Symp/PCR–), and
Symp/PCR1 HCWs. HCWs with negative S protein–specific IgA serum values are labeled individually. G-I, S
protein–specific IgA (top) and IgG (bottom) titers in tear fluid, including S1-specific (G), ECD-specific (H), and
RBD-specific IgA and IgG (I) of S1 protein–seronegative individuals in the HCWmucosal subgroup. (J-L) Linear
modeling of S1 protein–specific IgA titers in serum (J) and nasal fluids (K) and total IgA in nasal fluids (L), as a
function of age in S1 protein–seronegative individuals in the HCW mucosal subgroup.
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by augmenting proinflammatory monocytes in the lungs. Howev-
er, trials with convalescent serum treatments have shown prom-
ising results during the current COVID-19 pandemic and also in
SARS-CoV.43Another caveat relates to the durability of protective
humoral immunity. Whether S protein–specific mucosal IgA
responses confer immunity to a secondary infection with SARS-
CoV-2 remains to be seen. We are currently characterizing the
cellular immune responses to SARS-CoV-2 and following up
our patient cohort longitudinally to address these important
issues.44,45
We thank Alessandra Guaita, Jennifer J€orger, Mitchell Levesque, Daniel
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members of the Boyman laboratory for helpful discussions and support. We
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Clinical implications: Measurement of SARS-CoV-2–specific
serum IgA and IgG titers in asymptomatic patients might un-
derestimate the prevalence of infected individuals.
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FIG E1. S protein–specific serum IgA and IgG values compared with sampling time point, disease severity,
patient age, and sex. A, Comparison of days between reported symptom onset and sample collection in pa-
tients with mild (n 5 26) versus severe COVID-19 (n 5 38). B, Visualization of age distribution in the gener-
alized additive models of S1 protein–specific IgA and IgG serum titers as a function of days between
reported symptom onset and sample collection. Comparison of patients with mild (n 5 26) versus severe
cases (n 5 38). C and D, Comparison of S1 protein–specific serum IgA (C) and IgG (D) titers in male (n 5
35) versus female (n 5 29) patients with COVID-19. The average times between reported symptom onset
and sample collection were 17 days (median 13 days) in male patients and 18 days (median 14 days) in fe-
male patients.
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All cases (n = 64)
p = 0.0003
FIG E2. Distribution of disease severity and age of the patients with COVID-
19. Comparison in all patients with COVID-19 (n 5 64) of patient age
distribution with COVID-19 severity at the time of sample collection,
ranging from mild COVID-19 to severe ARDS, as defined by the World
Health Organization classification criteria.14 P valuewas computed by using
the Kruskal-Wallis test.
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FIG E3. S protein–specific serum IgA and IgG values compared with severity of symptoms of patients with
COVID-19. A and B, Comparison of S1 protein–specific serum IgA (A) and IgG (B) titers with disease severity
in our cohort of patients with COVID-19 (n5 64), ranging frommild COVID-19 to severe ARDS, as defined by
the World Health Organization classification criteria.14 Data are shown as boxplots. Each dot represents an
independent and unrelated donor. The significance of between-group differencies was explored by using
the Kruskal-Wallis test.
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FIG E4. Longitudinal measurement of S protein–specific serum IgA and IgG values in asymptomatic
controls and severe cases of COVID-19. A and B, S1 protein–specific serum IgA (top) and IgG (bottom) titers
in asymptomatic donors (n 5 4) (A) and patients with severe cases of COVID-19 (n 5 3) (B). The connected
dots represent sequential measurements of the same individual.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
CERVIA ET AL 13.e4
FIG E5. Titration of nasal fluids to detect S protein–specific IgA and IgG.
Measurement of S1 protein–specific IgA (top) and IgG (bottom) by using
different dilutions of nasal fluids in a subset of the HCW mucosal subgroup
(n 5 15).
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FIG E6. Comparison of immunoassays to measure S protein–specific IgA and IgG in samples from serum,
tears, nasal fluid, and saliva. Comparison of OD ratios of IgA (top) and IgG (bottom) obtained with a com-
mercial ELISA specific for the S1 protein of SARS-CoV-2 (x-axes) and the inflection point of the sigmoidal
curve (–log(EC50) (y-axes), the latter determined by measuring IgA (top) and IgG (bottom) against SARS-
CoV-2 S ECD and SARS-CoV-2 S1 protein RBD in serial dilutions using an in-house immunoassay (see
the Methods section). S protein–specific IgA (top) and IgG (bottom) were measured in serum, tear fluid,
nasal fluid, and saliva of members of the HCW mucosal subgroup. Data are shown as scatter plots. Each
dot represents an independent and unrelated donor. The Spearman correlation coefficient (r) is shown
with the corresponding P value.
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FIG E7. Analysis of total IgA and IgG serum titers in the HCW mucosal subgroup. Total IgA (top) and IgG
(bottom) titers in serum, tear fluid, nasal fluid, and saliva were assessed in individuals in the HCW mucosal
subgroup who tested negative for S1 protein–specific serum IgA (top) and IgG (bottom). The results of a
comparison of aymptomatic, PCR-negative (Asymp/PCR–), symptomatic PCR-negative (Symp/PCR–), and
symptomatic, PCR-positive (Symp/PCR1) HCWs are shown. Four PCR-negative HCWs with negative S
protein–specific IgA values in their serum but increased S protein–specific IgA titers in their nasal fluids
are labeled with their corresponding study code. The significance of between-group differences was
explored by using the Wilcoxon test.
J ALLERGY CLIN IMMUNOL
nnn 2020
13.e7 CERVIA ET AL
FIG E8. SARS-CoV-2 neutralization in nasal and tear fluids of individuals testing negative for SARS-CoV-2–
specific antibodies in serum. A, Representative photographs of SARS-CoV-2–infected VeroE6 cells, showing
either absent, partial, or full neutralization of SARS-CoV-2 in the presence or absence of patient serum. B,
Shown are the proportions of full (red), partial (orange), and absent (blue) neutralizing ability of serum
(n 5 20), nasal fluid (n 5 26), and tear fluid samples (n 5 7) obtained from the HCW subgroup with either
positive to borderline (top row) or negative (bottom row) S1 protein–specific IgA and IgG titers in their
serum.
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FIG E9. Mucosal S protein–specific IgA and IgG in 2 patients with mild
COVID-19. Shown are S1 protein–specific IgA and IgG titers in the nasal
fluids of patients COV2-A0013 and COV2-A0014 (see Fig 3) on day 25.
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